About Qiagen
Qiagen is a publicly listed company based in Hilden (Germany) founded in 1984 by Metin Colpan and Jurgen Schumacher, and was acquired by Thermo Fisher Scientific in March 2020. Products and reagents for molecular diagnostic assays are supplied. The company has 5,760 employees. Qiagen has completed 24 acquisitions, including AmniSure, Artus Biotech and Blirt. Its chief executive, as recorded, is Metin Colpan. Its website qiagen.com draws about 458 thousand monthly visits. Its Indian entity Qiagen India Private Limited reported revenue of ₹212 Cr. Qiagen offers products and services including QIAcuityDx, QIAwave Kits, Proteinase K, and TissueLyser III. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Kits and Reagents.
Company details
Qiagen was founded in 1984 in Hilden, Germany, and operates in the biotechnology sector. Molecular diagnostic assays are supported through products that isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. Reagents for PCR, sequencing, detection, automated systems, analytics software, RNAi, epigenetics, and laboratory essentials are provided to research and clinical applications worldwide.
- Headquarters Hilden, Germany
- Employees 5,760
- Founders Metin Colpan, Jurgen Schumacher
- Stage Acquired
- SectorsHealthcare
- Website category Science and Education · Biology
- Website qiagen.com/us
- Social LinkedIn X Facebook Instagram YouTube
- Acquired by Thermo Fisher Scientific (Mar 2020)
- Legal Name Qiagen India Private Limited
- Date of Incorporation 11 Dec, 2009
- Jurisdiction New Delhi, Delhi, India
- Indian entity revenue₹212 Cr
FY 2025 · +9% YoY
- Indian entity net profit₹12.01 Cr
FY 2025 · 6% margin
- Indian entity EBITDA₹21.46 Cr
FY 2025 · 10% margin
- Latest Funding Round$60.64K (USD), Grant
Jan 2022
- InvestorsThermo Fisher Scientific
& 3 more
- Employee Count5,760
- Investments & AcquisitionsAmniSure
& 23 more
- Acquired byThermo Fisher Scientific
(Mar 2020)
Associated legal entities of Qiagen
Qiagen operates through Qiagen India Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Qiagen India Private Limited CIN U74900DL2009PTC196804 | Active | 11 Dec 2009 | New Delhi, Delhi | ₹212 Cr | 111 | 5 | View details |
Products & Services of Qiagen
Qiagen offers a comprehensive portfolio of products and services, including QIAcuityDx, QIAwave Kits, Proteinase K, and TissueLyser III.
Fully automated system for accurate genetic variation detection and quantification
Eco-friendly kits for efficient DNA and RNA sample processing
Enzyme for protein digestion in biological sample preparation
Instrument for effective lysis of challenging biological samples
Apps and channels of Qiagen
its YouTube channel QIAGEN has 10.9K subscribers and 30 videos.
Videos from Qiagen
The most watched videos on Qiagen's YouTube channel, QIAGEN (10.9K subscribers). Click a video to play it here.
More on QIAGEN.
Funding Insights of Qiagen
- Total Rounds 13
- Last Round Grant — $60,643
- First Round $11.78M
(Oct 2007)
- Investors Count 3
Latest 10 of 13 funding rounds of Qiagen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2022 | $60,643 | Grant | – | – | |
| Jul 2021 | $614,431 | Grant | – | – | |
| Mar 2021 | $627,735 | Grant | – | – | |
| Dec 2020 | $500M | Post-IPO | – | – | – |
| Mar 2020 | $598,000 | Grant | – | – | |
| Feb 2019 | $252,954 | Grant | – | – | |
| Jan 2019 | $265,718 | Grant | – | – | |
| Jan 2019 | $25,786 | Grant | – | – | |
| Dec 2017 | $35,203 | Grant | – | – | |
| Jan 2017 | $392,438 | Grant | – | – |
4 investors in total: 4 institutional.
Investors in Qiagen
Qiagen has secured backing from 4 investors, including institutional investors. Prominent investors backing the company include Thermo Fisher Scientific, HHS and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Administers health care and support for military personnel and operations. | health.mil | Falls Church, United States | ||
Electron microscopy services and microanalysis instruments are provided. | 1956 | thermofisher.com | Waltham, United States |
Investor details for Qiagen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Qiagen India Private Limited (Qiagen)
Qiagen India Private Limited is the primary company behind Qiagen. The board of Qiagen India Private Limited currently have 4 directors; the longest-serving is Manoj Jagathmohan, appointed in 2013. 16 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Manoj Jagathmohan DIN 06798666 | Director | 26 Dec 2013 | 12 yrs 10 mo | Qiagen India Private Limited |
| Sanjay Mathur DIN 06431084 | Director | 11 Nov 2021 | 4 yrs 11 mo | Qiagen India Private Limited |
| Lin Xunlong DIN 10868696 | Additional Director | 12 Dec 2024 | 1 yr 10 mo | Qiagen India Private Limited |
| Axel Backheuer DIN 11434094 | Additional Director | 07 Jan 2026 | 10 mo | Qiagen India Private Limited |
People of Qiagen
385 people are tracked at Qiagen (133 in leadership, 9 in board & advisors, 243 in team); the tracked headcount is 5,760.
| Name | Role | Group |
|---|---|---|
Metin Colpan | Co-Founder & CEO | Leadership |
Jurgen Schumacher | Co-Founder | Leadership |
Thierry Bernard | Chief Executive Officer | Leadership |
Stephany Foster | SVP & Head, Human Resources | Leadership |
Antonio Santos | SVP & Head, Global Operations | Leadership |
Mike Evershed | Director, Project Management | Leadership |
Miriam Engels | Director, Head Of Global Talent Attraction And Acquisition | Leadership |
Bryan Burrell | Senior Sales Director | Leadership |
Christine Clarke | Senior Director, Head Of Quantiferon Sales North America | Leadership |
Jeffrey Durocher | Associate Director, Instrumentation Sales | Leadership |
Christian Houde | Senior Director Program Management, Global Operations | Leadership |
Andrew Critchley | Vp, Head Of Service Solutions EMEA And MD Qiagen Ltd | Leadership |
Danilo Oliveira | Finance Director Head For Latam | Leadership |
Thomas Fleury | Associate Director Sales Mdx | Leadership |
Kevin Gonsoulin | Sr Director, Corporate Accounts North America | Leadership |
Isabell Herrmann | Associate Director Project Management | Leadership |
Thomas Schoenig | Head Of Project Management EMEA | Leadership |
Jing Kang | Associate Director, Global Project Management | Leadership |
Daniel Gyr | Senior Director Human Resources - Head Of Labour Relations & Global HR Policies And Compliance | Leadership |
Mohammed Alsadi | Associate Director Sales Quantiferon Middle East | Leadership |
365 more people are available in the full profile.
Complete people profiles for Qiagen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Qiagen
Qiagen is a publicly listed company on the NYSE with ticker symbol QGEN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date25 Sep 1997
- Listed onFRA: QIA
- Listed entityQiagen N.V.
- Exchange sectorHealth technology
Financials of Qiagen
Figures of Qiagen India Private Limited, the primary company behind Qiagen, for FY 2025. Revenue was ₹212 Cr (+9% year on year). Net profit was ₹12.01 Cr (6% margin). EBITDA was ₹21.46 Cr (10% margin). Revenue has grown at a compounded annual rate of +5% over three years and +7% over five years.
- ₹212 CrRevenue · FY 2025 · +9% YoY
- ₹12.01 CrNet profit · 6% margin
- ₹21.46 CrEBITDA · 10% margin
- ₹112 CrPaid-up capital
- 111Employees (provident fund records)
- +5%Revenue CAGR, 3 years
- +7%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Qiagen India Private Limited are on its company page.
Detailed financial statements for Qiagen
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Qiagen
Qiagen has strategically engaged in corporate development activities, having acquired 24 companies. Notable acquisitions include AmniSure, Artus Biotech and Blirt.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Genomic data is stored and managed through a cloud-based platform. | genoox.com | Tel Aviv, Israel | 2012 | May 2025 | $70M | |
A DNA sequencing platform for forensic science applications is developed. | verogen.com | San Diego, United States | 2017 | Jan 2023 | $150M | |
Specialty enzymes for nucleic acid purification and sequencing are produced. | blirt.eu | Gdansk, Poland | 2008 | May 2022 | •••• | |
Developer of a platform for low cost molecular testing | neumodx.com | Ann Arbor, United States | 2012 | Sep 2020 | $248M | |
Molecular profiles are analyzed for clinical decision support in oncology. | n-of-one.com | Lexington, United States | 2008 | Jan 2019 | •••• | |
Syndromic testing systems for respiratory and gastrointestinal pathogens are developed. | stat-dx.com | Barcelona, Spain | 2010 | Jan 2018 | $191M | |
Software for biomarker data management, visualization, and analysis is provided. | omicsoft.com | Cary, United States | 2007 | Jan 2017 | •••• | |
LNA-based tools are developed for diagnostics and research applications. | exiqon.com | Vedbaek, Denmark | 1995 | Mar 2016 | $103.66M | |
Provider of molecular diagnostic solutions | mobio.com | Carlsbad, United States | 1993 | Jan 2016 | •••• | |
Enzymes and DNA kits for next-generation sequencing are manufactured. | enzymatics.com | Beverly, United States | 2006 | •••• |
Complete acquisition details for Qiagen
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Qiagen
15 dated milestones of Qiagen across 41 years, from founding to its latest funding, stage changes and deals.
- Founded Qiagen is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $11.8M.
- Acquisition Acquires MO BIO Laboratories.
- Acquisition Acquires Exiqon.
- Acquisition Acquires Omicsoft Corporation.
- Acquisition Acquires STAT-Dx.
- Acquisition Acquires STATdx.
- Acquisition Acquires N-of-One.
- Exit Acquired by Thermo Fisher Scientific.
- Acquisition Acquires NeuMoDx.
- Funding Latest funding round, Grant, of $61K.
- Acquisition Acquires Blirt.
- Acquisition Acquires Verogen.
- Acquisition Acquires Genoox.
Web traffic of Qiagen
The website of Qiagen (qiagen.com) receives about 458.2K visits a month and ranks #105,023 among all websites worldwide, #6,732 in Biology.
- Monthly visits458.2K
▲ 0.8% vs previous month
- Unique visitors193.7K
per month
- Global rank#105,023
among all websites
- Category rank#6,732
Science and Education · Biology
- Bounce rate40%
- Pages per visit2.8
- Average visit2 min 12 sec
- DevicesDesktop 56% · Mobile 44%
Websites whose visitors overlap most with Qiagen. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| bio-rad.com | 100% | 665.2K | #79,666 | View details | |
| neb.com | 98% | 749.5K | #69,042 | View details | |
| sabiosciences.com | 88% | View details | |||
| zymoresearch.com | 86% | 138.3K | #306,279 | View details | |
promega.com | promega.com | 79% | #192,389 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Qiagen
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Qiagen
Complete news archive for Qiagen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Qiagen
Qiagen was founded in 1984 and raised its 1st funding round 23 years after it was founded.
Qiagen is headquartered in Hilden, Germany. It is registered at Hilden, North Rhine-westphalia, Germany.
Metin Colpan is the CEO of Qiagen, as recorded in our data. They have also founded this company.
Qiagen has 5,760 employees.
The primary company behind Qiagen, Qiagen India Private Limited, reported revenue of ₹212 Cr for FY 2025, up 9% year on year.
Qiagen was founded in 1984 in Hilden, Germany, and operates in the biotechnology sector. Molecular diagnostic assays are supported through products that isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. Reagents for PCR, sequencing, detection, automated systems, analytics software, RNAi, epigenetics, and laboratory essentials are provided to research and clinical applications worldwide.
Qiagen offers QIAcuityDx, QIAwave Kits, Proteinase K, and TissueLyser III.
Yes, Qiagen is publicly traded on NYSE under the ticker symbol QGEN.
Qiagen has made 24 acquisitions, including AmniSure, Artus Biotech, and Blirt.
Qiagen has 4 investors. Key investors include Thermo Fisher Scientific, HHS, European Union, and Military Health.
Qiagen operates through Qiagen India Private Limited.
Yes. Qiagen was acquired by Thermo Fisher Scientific in March 2020.